Corrona Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry
Latest Information Update: 17 Feb 2025
At a glance
- Drugs Abatacept (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary) ; Tofacitinib (Primary) ; Adalimumab; Anakinra; Antirheumatics; Certolizumab pegol; Disease-modifying antirheumatics; Etanercept; Golimumab; Infliximab; Prednisone; Rituximab; Tumour necrosis factor inhibitors
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CERTAIN; CorEvitas; CORRONA
Most Recent Events
- 01 Feb 2025 Results (N= 3,481) assessing the effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis were published in the Clinical Rheumatology
- 09 Nov 2021 Results (n=175) assessing treatment outcomes over a 12-month period among patients prescribed TNFi therapies as a first targeted treatment and stratified according to MSRC results presented at the ACR Convergence 2021
- 09 Nov 2021 Results of an analysis of Molecular Signature Response Classifier to predictive of inadequate response to TNFi presented at the ACR Convergence 2021